Debating Shelby

Sentiments expressed at a March 12 National Academy of Sciences workshop suggest that scientists and policy-makers remain very concerned about data access issues related to the now infamous Shelby Amendment. The amendment, a two-line provision added by Sen. Richard Shelby (R-Ala.) to an omnibus appropriations law for fiscal year 1999, subjects federally funded scientific research to requests for data made under the Freedom of Information Act (FOIA).1 Its inclusion sparked a debate between indust

Written byEugene Russo
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

After receiving thousands of public comments, the Office of Management and Budget (OMB) reinterpreted the amendment, reaffirming FOIA's privacy trade and secrecy protections, and limiting requested data to published or cited research used by the federal government in developing legally binding agency actions. Thus far, the legislation has not been extensively tested. The National Institutes of Health has granted only four FOIA requests and denied three. The Environmental Protection Agency has received only a handful of requests.

Many scientists and scientific institutions, including both the NAS and the Federation of American Societies for Experimental Biology, saw the OMB's interpretation as a big improvement. Several panelists at the NAS workshop approved as well, but they expressed continued concern. Workshop attendee E. William Colgazier, CEO of the NAS and the National Research Council, was hoping the OMB agreement would be acceptable to all interested parties. But after hearing discussion at the workshop, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies